396 related articles for article (PubMed ID: 28011389)
1. Extended-release naltrexone for pre-release prisoners: A randomized trial of medical mobile treatment.
Gordon MS; Vocci FJ; Fitzgerald TT; O'Grady KE; O'Brien CP
Contemp Clin Trials; 2017 Feb; 53():130-136. PubMed ID: 28011389
[TBL] [Abstract][Full Text] [Related]
2. Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): protocol for an evaluation of two randomized effectiveness trials.
Murphy SM; Jeng PJ; Poole SA; Jalali A; Vocci FJ; Gordon MS; Woody GE; Polsky D
Addict Sci Clin Pract; 2020 Apr; 15(1):15. PubMed ID: 32321570
[TBL] [Abstract][Full Text] [Related]
3. Initiation of extended release naltrexone (XR-NTX) for opioid use disorder prior to release from prison.
Friedmann PD; Wilson D; Hoskinson R; Poshkus M; Clarke JG
J Subst Abuse Treat; 2018 Feb; 85():45-48. PubMed ID: 28527855
[TBL] [Abstract][Full Text] [Related]
4. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community.
Di Paola A; Lincoln T; Skiest DJ; Desabrais M; Altice FL; Springer SA
Contemp Clin Trials; 2014 Nov; 39(2):256-68. PubMed ID: 25240704
[TBL] [Abstract][Full Text] [Related]
5. Injectable pharmacotherapy for opioid use disorders (IPOD).
Farabee D; Hillhouse M; Condon T; McCrady B; McCollister K; Ling W
Contemp Clin Trials; 2016 Jul; 49():70-7. PubMed ID: 27282118
[TBL] [Abstract][Full Text] [Related]
6. A Phase 4, Pilot, Open-Label Study of VIVITROL® (Extended-Release Naltrexone XR-NTX) for Prisoners.
Gordon MS; Kinlock TW; Vocci FJ; Fitzgerald TT; Memisoglu A; Silverman B
J Subst Abuse Treat; 2015 Dec; 59():52-8. PubMed ID: 26299956
[TBL] [Abstract][Full Text] [Related]
7. Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial.
Lee JD; McDonald R; Grossman E; McNeely J; Laska E; Rotrosen J; Gourevitch MN
Addiction; 2015 Jun; 110(6):1008-14. PubMed ID: 25703440
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of extended-release injectable naltrexone among incarcerated persons with opioid use disorder before release from prison versus after release.
Jalali A; Jeng PJ; Polsky D; Poole S; Ku YC; Woody GE; Murphy SM
J Subst Abuse Treat; 2022 Oct; 141():108835. PubMed ID: 35933942
[TBL] [Abstract][Full Text] [Related]
9. Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trial.
Lee JD; Friedmann PD; Boney TY; Hoskinson RA; McDonald R; Gordon M; Fishman M; Chen DT; Bonnie RJ; Kinlock TW; Nunes EV; Cornish JW; O'Brien CP
Contemp Clin Trials; 2015 Mar; 41():110-7. PubMed ID: 25602580
[TBL] [Abstract][Full Text] [Related]
10. Extended-release injectable naltrexone for opioid use disorder: a systematic review.
Jarvis BP; Holtyn AF; Subramaniam S; Tompkins DA; Oga EA; Bigelow GE; Silverman K
Addiction; 2018 Jul; 113(7):1188-1209. PubMed ID: 29396985
[TBL] [Abstract][Full Text] [Related]
11. Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community: Results of a Double-Blind, Placebo-Controlled Randomized Trial.
Springer SA; Di Paola A; Azar MM; Barbour R; Biondi BE; Desabrais M; Lincoln T; Skiest DJ; Altice FL
J Acquir Immune Defic Syndr; 2018 May; 78(1):43-53. PubMed ID: 29373393
[TBL] [Abstract][Full Text] [Related]
12. Extended-release naltrexone opioid treatment at jail reentry (XOR).
McDonald RD; Tofighi B; Laska E; Goldfeld K; Bonilla W; Flannery M; Santana-Correa N; Johnson CW; Leibowitz N; Rotrosen J; Gourevitch MN; Lee JD
Contemp Clin Trials; 2016 Jul; 49():57-64. PubMed ID: 27178765
[TBL] [Abstract][Full Text] [Related]
13. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.
Krupitsky E; Nunes EV; Ling W; Gastfriend DR; Memisoglu A; Silverman BL
Addiction; 2013 Sep; 108(9):1628-37. PubMed ID: 23701526
[TBL] [Abstract][Full Text] [Related]
14. A randomized comparison of extended-release naltrexone with or without patient navigation vs enhanced treatment-as-usual for incarcerated adults with opioid use disorder.
Farabee D; Condon T; Hallgren KA; McCrady B
J Subst Abuse Treat; 2020 Oct; 117():108076. PubMed ID: 32811623
[TBL] [Abstract][Full Text] [Related]
15. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community.
Springer SA; Altice FL; Herme M; Di Paola A
Contemp Clin Trials; 2014 Mar; 37(2):209-18. PubMed ID: 24384538
[TBL] [Abstract][Full Text] [Related]
16. Healthcare utilization in adults with opioid dependence receiving extended release naltrexone compared to treatment as usual.
Soares WE; Wilson D; Rathlev N; Lee JD; Gordon M; Nunes EV; O'Brien CP; Friedmann PD
J Subst Abuse Treat; 2018 Feb; 85():66-69. PubMed ID: 28576389
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial.
Solli KK; Latif ZE; Opheim A; Krajci P; Sharma-Haase K; Benth JŠ; Tanum L; Kunoe N
Addiction; 2018 Oct; 113(10):1840-1849. PubMed ID: 29806872
[TBL] [Abstract][Full Text] [Related]
18. Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial.
Bisaga A; Mannelli P; Yu M; Nangia N; Graham CE; Tompkins DA; Kosten TR; Akerman SC; Silverman BL; Sullivan MA
Drug Alcohol Depend; 2018 Jun; 187():171-178. PubMed ID: 29674251
[TBL] [Abstract][Full Text] [Related]
19. Incidence of future arrests in adults involved in the criminal justice system with opioid use disorder receiving extended release naltrexone compared to treatment as usual.
Soares WE; Wilson D; Gordon MS; Lee JD; Nunes EV; O'Brien CP; Shroff M; Friedmann PD
Drug Alcohol Depend; 2019 Jan; 194():482-486. PubMed ID: 30522048
[TBL] [Abstract][Full Text] [Related]
20. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
Krupitsky E; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Silverman BL
Lancet; 2011 Apr; 377(9776):1506-13. PubMed ID: 21529928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
